Navigation Links
AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
Date:4/4/2013

tly involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, the uncertain timing of completion of and the success of clinical trials and the potential problems that may arise in the clinical development process, the uncertain and time-consuming regulatory filing and approval process, the availability of resources to develop Rigel's product candidates, the uncertain therapeutic and commercial value of fostamatinib, market competition, risks associated with and Rigel's dependence on Rigel's corporate partnerships, as well as other risks detailed from time to time in Rigel's reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2012. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.CONTACTS Rigel Investor EnquiriesRaul RodriguezPhone: 650.624.1302Email: invrel@rigel.comRigel Media EnquiriesMedia Contact: Susan C. Rogers, Alchemy Consulting, Inc.Phone: 650.430.3777Email: susan@alchemyemail.comAstraZeneca Media EnquiriesEsra Erkal-Paler

+44 20 7604 8030 (UK/Global)Vanessa Rhodes

+44 20 7604 8037 (UK/Global)Ayesha Bharmal

+44 20 7604 8034 (UK/Global)Jacob Lund

+46 8 553 260 20 (Sweden)AstraZeneca Investor EnquiriesJames Ward-Lilley

+44 20 7604 8122

mob: +44 7785 432613Karl Hard

+44 20 7604 8123

mob: +44 7789 654364Colleen Proctor

+1 302 886 1842

mob: +1 302 357 4882Ed Seage

+1 302 886 4065

mob: +1 302 373 1361 


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
2. AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis
3. Genpact and AstraZeneca Win Outsourcing Center and SSON Awards
4. AstraZeneca Acquires Neuroscience Assets From Link Medicine
5. AstraZeneca and Leading Academic Scientists to Collaborate on Alzheimers Disease Research
6. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
7. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
8. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
9. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
10. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
11. AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... VIEW, Calif. , July 30, 2015 ... it will release its second quarter 2015 financial results ... 2015.   In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
(Date:7/30/2015)... SAN DIEGO , July 30, 2015 /PRNewswire/ ... a medical device company and manufacturer of the ... it has entered into non-exclusive Development Agreements with ... generation Tandem insulin pumps with the Dexcom G5 ... "Integrating Tandem,s next generation pump platform with ...
(Date:7/30/2015)... WASHINGTON , July 30, 2015  Today we bring you a special edition ... wanted to remind you about some of our Medicare resources and continue highlighting the ... Check out our latest infographics and videos ... ... ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
(Date:8/1/2015)... Greenwich, CT (PRWEB) , ... August 01, 2015 ... ... Great Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy ... incorporating it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier ...
(Date:8/1/2015)... ... ... BeverlyD, owner and founder of BeverlyD Luxe Organic Hair Care, has announced ... donation to kick off the campaign for healing and Well-Being. , BeverlyD has helped ... line of raw, organic hair care products, as well as her book, Hair Now!— ...
(Date:7/31/2015)... ... July 31, 2015 , ... That’s right, the ... the STASH awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, ... as tried-and-true products that have stood the test of time. These include lighting ...
(Date:7/31/2015)... Ind. (PRWEB) , ... August 01, 2015 , ... The ... the Global Advisory Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in ... invited to participate in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied ...
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only Thermage ... also the first provider of Exilis non-surgical fat reduction in New York. Due ... attracted a large International clientele. Many patients travel to New York to get ...
Breaking Medicine News(10 mins):Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4
... be removed through the nose using endoscopy rather than having ... this approach, doctors use tiny scopes and cameras to enter ... pulverizes and suctions. At points where the tumor adheres to ... drill is used to eliminate tumor cells in the underlying ...
... Swedish study, Women's Health in the Lund Area, ... of the data collected now reveals a small ... [EHP 113:1627-1631]//. This suggests that low-level cadmium exposure ... general population is likely to encounter low-level chronic ...
... new study, which appears in the October issue ... frequency of and early exposure to severe hypoglycemia ... ,Severe hypoglycemia is a significant and relatively ... type 1 diabetes. Repeated severe hypoglycemia has been ...
... frequently shows a sonographic pattern of ‘pneumonia’//. , ... The acoustic–physical conditions of the thorax produces the most serious ... , ... a method complementary to conventional X-ray examination. The sonographic pattern ...
... Health Minister Anbumani Ramadoss has said that the government is ... and plans to take several steps to check female foeticide, ... ,Dr Ramadoss said that there were plans to set up ... unfortunate practice that prevails on a large scale in the ...
... the first in United Kingdom to perform a Live Liver ... said that in 2006 five live liver operations would be ... live liver regeneration operation a part of liver is transplanted ... the donor and recipient, the regeneration to full size of ...
Cached Medicine News:Health News:Novel Technique For Management Of Inverted Papilloma Of Frontal Sinus 2Health News:The Exposure Of Cadmium And Its Effects On Kidneys 2Health News:Severe Hypoglycemia And Spatial Memory In Children With Type 1 Diabetes 2